bismuth has been researched along with Peritoneal Neoplasms in 6 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (33.33) | 18.2507 |
2000's | 2 (33.33) | 29.6817 |
2010's | 2 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Alke, A; Blechert, B; Bruchertseifer, F; Drecoll, E; Essler, M; Gaertner, FC; Miederer, M; Morgenstern, A; Müller, JM; Seidl, C; Senekowitsch-Schmidtke, R; Vallon, M | 1 |
Beck, R; Bruchertseifer, F; Quintanilla-Martinez, L; Seidl, C; Senekowitsch-Schmidtke, R; Zöckler, C | 1 |
Blechert, B; Bruchertseifer, F; Essler, M; Gärtner, FC; Morgenstern, A; Neff, F; Seidl, C; Senekowitsch-Schmidtke, R | 1 |
Apostolidis, C; Beck, R; Buchhorn, HM; Morgenstern, A; Saur, D; Schwaiger, M; Seidl, C; Senekowitsch-Schmidtke, R | 1 |
Atcher, RW; Culbertson, S; Rotmensch, J; Schwartz, JL; Whitlock, JL | 1 |
Alvarez, VL; Hauler, JA; Simonson, RB; Ultee, ME | 1 |
6 other study(ies) available for bismuth and Peritoneal Neoplasms
Article | Year |
---|---|
Treatment of peritoneal carcinomatosis by targeted delivery of the radio-labeled tumor homing peptide bi-DTPA-[F3]2 into the nucleus of tumor cells.
Topics: Animals; Antineoplastic Agents; Bismuth; Cell Line, Tumor; Cell Nucleus; Drug Delivery Systems; Endocytosis; Humans; Isotope Labeling; Mice; Pentetic Acid; Peptides; Peritoneal Neoplasms; Radioisotopes; Tissue Distribution; Xenograft Model Antitumor Assays | 2009 |
177Lu-immunotherapy of experimental peritoneal carcinomatosis shows comparable effectiveness to 213Bi-immunotherapy, but causes toxicity not observed with 213Bi.
Topics: Animals; Antibodies, Monoclonal; Bismuth; Blood Cell Count; Cell Line, Tumor; Disease Models, Animal; Drug Stability; Female; Humans; Immunoconjugates; Lutetium; Mice; Peritoneal Neoplasms; Radioimmunotherapy; Radioisotopes; Radiotherapy Dosage; Stomach Neoplasms; Time Factors | 2011 |
Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis.
Topics: Actinium; Animals; Bismuth; Cell Line, Tumor; Disease Models, Animal; Heterocyclic Compounds, 1-Ring; Humans; Isotope Labeling; Kidney; Mice; Organometallic Compounds; Pentetic Acid; Peptides; Peritoneal Neoplasms; Radioisotopes; Treatment Outcome; Xenograft Model Antitumor Assays | 2012 |
Non-invasive visualisation of the development of peritoneal carcinomatosis and tumour regression after 213Bi-radioimmunotherapy using bioluminescence imaging.
Topics: Animals; Bismuth; Cell Line, Tumor; Diagnostic Imaging; Luciferases; Luminescence; Mice; Mice, Nude; Neoplasm Transplantation; Peritoneal Neoplasms; Radioimmunotherapy; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Stomach Neoplasms; Transfection | 2007 |
Comparison of sensitivities of cells to X-ray therapy, chemotherapy, and isotope therapy using a tumor spheroid model.
Topics: Animals; Bismuth; Cisplatin; Cricetinae; Cricetulus; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Peritoneal Neoplasms; Radioisotopes; Radiotherapy; Tumor Cells, Cultured | 1994 |
Radioimmunotherapy of peritoneal human colon cancer xenografts with site-specifically modified 212Bi-labeled antibody.
Topics: Animals; Antibodies, Monoclonal; Bismuth; Colonic Neoplasms; Humans; Mice; Neoplasm Transplantation; Peritoneal Neoplasms; Radioisotopes; Survival Rate; Transplantation, Heterologous | 1990 |